康复新液联合生长抑素治疗肝硬化上消化道出血的临床效果及对血流动力学的影响

Clinical effect of Kangfuxin Solution combined with Somatostatin in the treatment of upper gastrointestinal hemorrhage of liver cirrhosis and its influence on hemodynamics

目的探讨康复新液联合生长抑素治疗肝硬化门脉高压性上消化道出血的临床效果及对血流动力学的影响。方法选取2017年1月～2018年6月九江市第一人民医院收治的84例肝硬化门脉高压性上消化道出血的患者作为研究对象,随机分为病例组和对照组,每组各42例。对照组给予常规支持治疗+生长抑素,病例组在对照组的基础上加用康复新液。观察两组患者的临床疗效、止血时间、输血量、再出血率、住院时间、静脉血流量以及不良反应发生情况。结果病例组的总有效率为95.24%,高于对照组的80.95%,差异有统计学意义(P<0.05);病例组的止血时间、住院时间均短于对照组,输血量少于对照组,再出血率低于对照组,差异有统计学意义(P<0.05)。病例组治疗后的门静脉血流量、脾静脉血流量均少于对照组,差异有统计学意义(P<0.05)。病例组的不良反应总发生率为4.76%,低于对照组的23.81%,差异有统计学意义(P<0.05)。结论康复新液联合生长抑素治疗肝硬化门脉高压性上消化道出血的临床效果显著,能更好地快速止血,降低不良反应发生率,值得临床推广。

Objective To explore the clinical efficacy of Kangfuxin Solution combined with somatostatin on cirrhotic portal hypertensive upper gastrointestinal bleeding and its influence on hemodynamics. Methods A total of 84 patients with cirrhotic portal hypertensive upper gastrointestinal hemorrhage admitted to the First People′s Hospital of Jiujiang City from January 2017 to June 2018 were selected and randomly divided into the case group and the control group, 42 cases in each group. The control group was given conventional supportive therapy and Somatostatin, the case group was supplemented with Kangfuxin Solution on the basis of the control group. The clinical efficacy, hemostasis time, blood transfusion volume, rebleeding rate, hospitalization time, venous blood flow and adverse reactions were observed in the two groups. Results The total effective rate of the case group was 95.24%, which was higher than that of the control group (80.95%), and the difference was statistically significant (P<0.05). The hemostasis time and the hospitalization time in the case group were shorter than those in the control group, the transfusion volume was less than that of the control group, and the rebleeding rate in the case group was lower than that in the control group, and the differences were statistically significant (P<0.05). After treatment, the portal venous blood flow and splenic venous blood flow in the case group were less than those in the control group, and the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the case group was 4.76%, which was lower than 23.81% in the control group, and the difference was statistically significant (P<0.05). Conclusion Kangfuxin Solution combined with Somatostatin in the treatment of cirrhotic portal hypertensive upper gastrointestinal bleeding has significant clinical effect, and can achieve faster hemostasis and lower incidence of adverse reactions, thus it is worthy of clinical promotion.